| No. |
KEGG PATHWAY * On map, Yellow: Drug target, Red: Disease-related |
KEGG GENES * [Number of genes] |
KEGG DRUG * |
DrugBank |
Disease ID * [Number of diseases] |
| 1 | Acute myeloid leukemia 2 genes, 4 drugs (DrugBank), 40 diseases shown |
[1] KIT |
D01441 |
Imatinib |
[11] 13, 28, 34, 35, 46, 51, 85, 86, 87, 89, 162 |
| D08066 |
| [1] MTOR |
D02714 |
Everolimus |
[9] 34, 67, 89, 96, 137, 157, 158, 228, 277 |
| D00753 |
Sirolimus |
[36] 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
| D06068 |
Temsirolimus |
[4] 13, 34, 89, 331 |
| 2 | Adherens junction 3 genes, 3 drugs (DrugBank), 8 diseases shown |
[1] EGFR |
D03455 |
Cetuximab |
[5] 34, 51, 86, 89, 331 |
| [1] FGFR1 |
D10481 |
Nintedanib |
[4] 51, 85, 89, 228 |
| [1] SRC |
D09664 |
Saracatinib |
[2] 6, 89 |
| 3 | Adipocytokine signaling pathway 1 gene, 3 drugs (DrugBank), 37 diseases shown |
[1] MTOR |
D02714 |
Everolimus |
[9] 34, 67, 89, 96, 137, 157, 158, 228, 277 |
| D00753 |
Sirolimus |
[36] 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
| D06068 |
Temsirolimus |
[4] 13, 34, 89, 331 |
| 4 | Adrenergic signaling in cardiomyocytes 1 gene, 1 drug (DrugBank), 13 diseases shown |
[1] ADRB2 |
D02147 |
Salbutamol |
[13] 3, 11, 12, 13, 49, 85, 86, 89, 113, 228, 231, 256, 299 |
| 5 | AGE-RAGE signaling pathway in diabetic complications 1 gene, 1 drug (DrugBank), 9 diseases shown |
[1] VEGFA |
D06409 |
Bevacizumab |
[9] 13, 34, 85, 86, 87, 89, 227, 280, 331 |
| 6 | Alanine, aspartate and glutamate metabolism 4 genes, 1 drug (DrugBank), 14 diseases shown |
[4] ABAT, ALDH5A1, GAD1, GAD2 |
D00399 |
Valproic Acid |
[14] 2, 3, 5, 8, 26, 34, 65, 89, 90, 102, 222, 233, 256, 331 |
| 7 | Aldosterone synthesis and secretion 3 genes, 1 drug (DrugBank), 14 diseases shown |
[3] CACNA1G, CACNA1H, CACNA1I |
D00399 |
Valproic Acid |
[14] 2, 3, 5, 8, 26, 34, 65, 89, 90, 102, 222, 233, 256, 331 |
| 8 | AMPK signaling pathway 2 genes, 4 drugs (DrugBank), 46 diseases shown |
[1] HMGCR |
D00434 |
Simvastatin |
[19] 6, 13, 15, 34, 46, 49, 51, 66, 79, 86, 89, 94, 158, 162, 195, 265, 298, 299, 310 |
| [1] MTOR |
D02714 |
Everolimus |
[9] 34, 67, 89, 96, 137, 157, 158, 228, 277 |
| D00753 |
Sirolimus |
[36] 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
| D06068 |
Temsirolimus |
[4] 13, 34, 89, 331 |
| 9 | Apelin signaling pathway 1 gene, 3 drugs (DrugBank), 37 diseases shown |
[1] MTOR |
D02714 |
Everolimus |
[9] 34, 67, 89, 96, 137, 157, 158, 228, 277 |
| D00753 |
Sirolimus |
[36] 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
| D06068 |
Temsirolimus |
[4] 13, 34, 89, 331 |
| 10 | Arachidonic acid metabolism 1 gene, 1 drug (DrugBank), 9 diseases shown |
[1] PTGS2 |
D00567 |
Celecoxib |
[9] 2, 3, 34, 46, 70, 89, 96, 161, 271 |
| 11 | Autophagy - animal 1 gene, 3 drugs (DrugBank), 37 diseases shown |
[1] MTOR |
D02714 |
Everolimus |
[9] 34, 67, 89, 96, 137, 157, 158, 228, 277 |
| D00753 |
Sirolimus |
[36] 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
| D06068 |
Temsirolimus |
[4] 13, 34, 89, 331 |
| 12 | Autophagy - other 1 gene, 3 drugs (DrugBank), 37 diseases shown |
[1] MTOR |
D02714 |
Everolimus |
[9] 34, 67, 89, 96, 137, 157, 158, 228, 277 |
| D00753 |
Sirolimus |
[36] 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
| D06068 |
Temsirolimus |
[4] 13, 34, 89, 331 |
| 13 | Axon guidance 2 genes, 2 drugs (DrugBank), 12 diseases shown |
[1] ABL1 |
D01441 |
Imatinib |
[11] 13, 28, 34, 35, 46, 51, 85, 86, 87, 89, 162 |
| D08066 |
| [2] ABL1, SRC |
D09664 |
Saracatinib |
[2] 6, 89 |
| 14 | Bacterial invasion of epithelial cells 1 gene, 1 drug (DrugBank), 2 diseases shown |
[1] SRC |
D09664 |
Saracatinib |
[2] 6, 89 |
| 15 | beta-Alanine metabolism 3 genes, 1 drug (DrugBank), 14 diseases shown |
[3] ABAT, GAD1, GAD2 |
D00399 |
Valproic Acid |
[14] 2, 3, 5, 8, 26, 34, 65, 89, 90, 102, 222, 233, 256, 331 |
| 16 | Bile secretion 1 gene, 1 drug (DrugBank), 19 diseases shown |
[1] HMGCR |
D00434 |
Simvastatin |
[19] 6, 13, 15, 34, 46, 49, 51, 66, 79, 86, 89, 94, 158, 162, 195, 265, 298, 299, 310 |
| 17 | Bladder cancer 4 genes, 4 drugs (DrugBank), 12 diseases shown |
[1] EGFR |
D03455 |
Cetuximab |
[5] 34, 51, 86, 89, 331 |
| [1] FGFR3 |
D10481 |
Nintedanib |
[4] 51, 85, 89, 228 |
| [1] SRC |
D09664 |
Saracatinib |
[2] 6, 89 |
| [1] VEGFA |
D06409 |
Bevacizumab |
[9] 13, 34, 85, 86, 87, 89, 227, 280, 331 |
| 18 | Breast cancer 5 genes, 6 drugs (DrugBank), 40 diseases shown |
[1] EGFR |
D03455 |
Cetuximab |
[5] 34, 51, 86, 89, 331 |
| [2] FGFR1, FLT4 |
D10481 |
Nintedanib |
[4] 51, 85, 89, 228 |
| [1] KIT |
D01441 |
Imatinib |
[11] 13, 28, 34, 35, 46, 51, 85, 86, 87, 89, 162 |
| D08066 |
| [1] MTOR |
D02714 |
Everolimus |
[9] 34, 67, 89, 96, 137, 157, 158, 228, 277 |
| D00753 |
Sirolimus |
[36] 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
| D06068 |
Temsirolimus |
[4] 13, 34, 89, 331 |
| 19 | Butanoate metabolism 4 genes, 1 drug (DrugBank), 14 diseases shown |
[4] ABAT, ALDH5A1, GAD1, GAD2 |
D00399 |
Valproic Acid |
[14] 2, 3, 5, 8, 26, 34, 65, 89, 90, 102, 222, 233, 256, 331 |
| 20 | C-type lectin receptor signaling pathway 2 genes, 2 drugs (DrugBank), 10 diseases shown |
[1] PTGS2 |
D00567 |
Celecoxib |
[9] 2, 3, 34, 46, 70, 89, 96, 161, 271 |
| [1] SRC |
D09664 |
Saracatinib |
[2] 6, 89 |
| 21 | Calcium signaling pathway 7 genes, 5 drugs (DrugBank), 30 diseases shown |
[1] ADRB2 |
D02147 |
Salbutamol |
[13] 3, 11, 12, 13, 49, 85, 86, 89, 113, 228, 231, 256, 299 |
| [3] CACNA1G, CACNA1H, CACNA1I |
D00399 |
Valproic Acid |
[14] 2, 3, 5, 8, 26, 34, 65, 89, 90, 102, 222, 233, 256, 331 |
| [1] EGFR |
D03455 |
Cetuximab |
[5] 34, 51, 86, 89, 331 |
| [1] PDGFRA |
D01441 |
Imatinib |
[11] 13, 28, 34, 35, 46, 51, 85, 86, 87, 89, 162 |
| D08066 |
| [2] PDGFRA, PDGFRB |
D10481 |
Nintedanib |
[4] 51, 85, 89, 228 |
| 22 | cAMP signaling pathway 2 genes, 2 drugs (DrugBank), 19 diseases shown |
[1] ADRB2 |
D02147 |
Salbutamol |
[13] 3, 11, 12, 13, 49, 85, 86, 89, 113, 228, 231, 256, 299 |
| [1] SSTR2 |
D00442 |
Octreotide |
[8] 67, 75, 84, 85, 89, 96, 193, 227 |
| D06495 |
| 23 | Cell cycle 1 gene, 2 drugs (DrugBank), 12 diseases shown |
[1] ABL1 |
D01441 |
Imatinib |
[11] 13, 28, 34, 35, 46, 51, 85, 86, 87, 89, 162 |
| D08066 |
| D09664 |
Saracatinib |
[2] 6, 89 |
| 24 | Cellular senescence 1 gene, 3 drugs (DrugBank), 37 diseases shown |
[1] MTOR |
D02714 |
Everolimus |
[9] 34, 67, 89, 96, 137, 157, 158, 228, 277 |
| D00753 |
Sirolimus |
[36] 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
| D06068 |
Temsirolimus |
[4] 13, 34, 89, 331 |
| 25 | Central carbon metabolism in cancer 8 genes, 6 drugs (DrugBank), 40 diseases shown |
[1] EGFR |
D03455 |
Cetuximab |
[5] 34, 51, 86, 89, 331 |
| [5] FGFR1, FGFR2, FGFR3, PDGFRA, PDGFRB |
D10481 |
Nintedanib |
[4] 51, 85, 89, 228 |
| [2] KIT, PDGFRA |
D01441 |
Imatinib |
[11] 13, 28, 34, 35, 46, 51, 85, 86, 87, 89, 162 |
| D08066 |
| [1] MTOR |
D02714 |
Everolimus |
[9] 34, 67, 89, 96, 137, 157, 158, 228, 277 |
| D00753 |
Sirolimus |
[36] 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
| D06068 |
Temsirolimus |
[4] 13, 34, 89, 331 |
| 26 | cGMP-PKG signaling pathway 1 gene, 1 drug (DrugBank), 13 diseases shown |
[1] ADRB2 |
D02147 |
Salbutamol |
[13] 3, 11, 12, 13, 49, 85, 86, 89, 113, 228, 231, 256, 299 |
| 27 | Chemical carcinogenesis 1 gene, 1 drug (DrugBank), 9 diseases shown |
[1] PTGS2 |
D00567 |
Celecoxib |
[9] 2, 3, 34, 46, 70, 89, 96, 161, 271 |
| 28 | Chemokine signaling pathway 1 gene, 1 drug (DrugBank), 2 diseases shown |
[1] SRC |
D09664 |
Saracatinib |
[2] 6, 89 |
| 29 | Choline metabolism in cancer 4 genes, 6 drugs (DrugBank), 40 diseases shown |
[1] EGFR |
D03455 |
Cetuximab |
[5] 34, 51, 86, 89, 331 |
| [1] MTOR |
D02714 |
Everolimus |
[9] 34, 67, 89, 96, 137, 157, 158, 228, 277 |
| D00753 |
Sirolimus |
[36] 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
| D06068 |
Temsirolimus |
[4] 13, 34, 89, 331 |
| [1] PDGFRA |
D01441 |
Imatinib |
[11] 13, 28, 34, 35, 46, 51, 85, 86, 87, 89, 162 |
| D08066 |
| [2] PDGFRA, PDGFRB |
D10481 |
Nintedanib |
[4] 51, 85, 89, 228 |
| 30 | Chronic myeloid leukemia 1 gene, 2 drugs (DrugBank), 12 diseases shown |
[1] ABL1 |
D01441 |
Imatinib |
[11] 13, 28, 34, 35, 46, 51, 85, 86, 87, 89, 162 |
| D08066 |
| D09664 |
Saracatinib |
[2] 6, 89 |
| 31 | Circadian entrainment 3 genes, 1 drug (DrugBank), 14 diseases shown |
[3] CACNA1G, CACNA1H, CACNA1I |
D00399 |
Valproic Acid |
[14] 2, 3, 5, 8, 26, 34, 65, 89, 90, 102, 222, 233, 256, 331 |
| 32 | Colorectal cancer 2 genes, 4 drugs (DrugBank), 37 diseases shown |
[1] EGFR |
D03455 |
Cetuximab |
[5] 34, 51, 86, 89, 331 |
| [1] MTOR |
D02714 |
Everolimus |
[9] 34, 67, 89, 96, 137, 157, 158, 228, 277 |
| D00753 |
Sirolimus |
[36] 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
| D06068 |
Temsirolimus |
[4] 13, 34, 89, 331 |
| 33 | Cortisol synthesis and secretion 3 genes, 1 drug (DrugBank), 14 diseases shown |
[3] CACNA1G, CACNA1H, CACNA1I |
D00399 |
Valproic Acid |
[14] 2, 3, 5, 8, 26, 34, 65, 89, 90, 102, 222, 233, 256, 331 |
| 34 | Cushing syndrome 4 genes, 2 drugs (DrugBank), 16 diseases shown |
[3] CACNA1G, CACNA1H, CACNA1I |
D00399 |
Valproic Acid |
[14] 2, 3, 5, 8, 26, 34, 65, 89, 90, 102, 222, 233, 256, 331 |
| [1] EGFR |
D03455 |
Cetuximab |
[5] 34, 51, 86, 89, 331 |
| 35 | EGFR tyrosine kinase inhibitor resistance 9 genes, 8 drugs (DrugBank), 42 diseases shown |
[1] EGFR |
D03455 |
Cetuximab |
[5] 34, 51, 86, 89, 331 |
| [5] FGFR2, FGFR3, KDR, PDGFRA, PDGFRB |
D10481 |
Nintedanib |
[4] 51, 85, 89, 228 |
| [1] MTOR |
D02714 |
Everolimus |
[9] 34, 67, 89, 96, 137, 157, 158, 228, 277 |
| D00753 |
Sirolimus |
[36] 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
| D06068 |
Temsirolimus |
[4] 13, 34, 89, 331 |
| [1] PDGFRA |
D01441 |
Imatinib |
[11] 13, 28, 34, 35, 46, 51, 85, 86, 87, 89, 162 |
| D08066 |
| [1] SRC |
D09664 |
Saracatinib |
[2] 6, 89 |
| [1] VEGFA |
D06409 |
Bevacizumab |
[9] 13, 34, 85, 86, 87, 89, 227, 280, 331 |
| 36 | Endocrine resistance 3 genes, 5 drugs (DrugBank), 38 diseases shown |
[1] EGFR |
D03455 |
Cetuximab |
[5] 34, 51, 86, 89, 331 |
| [1] MTOR |
D02714 |
Everolimus |
[9] 34, 67, 89, 96, 137, 157, 158, 228, 277 |
| D00753 |
Sirolimus |
[36] 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
| D06068 |
Temsirolimus |
[4] 13, 34, 89, 331 |
| [1] SRC |
D09664 |
Saracatinib |
[2] 6, 89 |
| 37 | Endocytosis 5 genes, 4 drugs (DrugBank), 14 diseases shown |
[1] EGFR |
D03455 |
Cetuximab |
[5] 34, 51, 86, 89, 331 |
| [3] FGFR2, FGFR3, PDGFRA |
D10481 |
Nintedanib |
[4] 51, 85, 89, 228 |
| [1] PDGFRA |
D01441 |
Imatinib |
[11] 13, 28, 34, 35, 46, 51, 85, 86, 87, 89, 162 |
| D08066 |
| [1] SRC |
D09664 |
Saracatinib |
[2] 6, 89 |
| 38 | Endometrial cancer 1 gene, 1 drug (DrugBank), 5 diseases shown |
[1] EGFR |
D03455 |
Cetuximab |
[5] 34, 51, 86, 89, 331 |
| 39 | Epithelial cell signaling in Helicobacter pylori infection 2 genes, 2 drugs (DrugBank), 6 diseases shown |
[1] EGFR |
D03455 |
Cetuximab |
[5] 34, 51, 86, 89, 331 |
| [1] SRC |
D09664 |
Saracatinib |
[2] 6, 89 |
| 40 | ErbB signaling pathway 4 genes, 6 drugs (DrugBank), 41 diseases shown |
[1] ABL1 |
D01441 |
Imatinib |
[11] 13, 28, 34, 35, 46, 51, 85, 86, 87, 89, 162 |
| D08066 |
| [2] ABL1, SRC |
D09664 |
Saracatinib |
[2] 6, 89 |
| [1] EGFR |
D03455 |
Cetuximab |
[5] 34, 51, 86, 89, 331 |
| [1] MTOR |
D02714 |
Everolimus |
[9] 34, 67, 89, 96, 137, 157, 158, 228, 277 |
| D00753 |
Sirolimus |
[36] 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
| D06068 |
Temsirolimus |
[4] 13, 34, 89, 331 |
| 41 | Estrogen signaling pathway 2 genes, 2 drugs (DrugBank), 6 diseases shown |
[1] EGFR |
D03455 |
Cetuximab |
[5] 34, 51, 86, 89, 331 |
| [1] SRC |
D09664 |
Saracatinib |
[2] 6, 89 |
| 42 | Fluid shear stress and atherosclerosis 3 genes, 3 drugs (DrugBank), 12 diseases shown |
[1] KDR |
D10481 |
Nintedanib |
[4] 51, 85, 89, 228 |
| [1] SRC |
D09664 |
Saracatinib |
[2] 6, 89 |
| [1] VEGFA |
D06409 |
Bevacizumab |
[9] 13, 34, 85, 86, 87, 89, 227, 280, 331 |
| 43 | Focal adhesion 8 genes, 5 drugs (DrugBank), 16 diseases shown |
[1] EGFR |
D03455 |
Cetuximab |
[5] 34, 51, 86, 89, 331 |
| [5] FLT1, FLT4, KDR, PDGFRA, PDGFRB |
D10481 |
Nintedanib |
[4] 51, 85, 89, 228 |
| [1] PDGFRA |
D01441 |
Imatinib |
[11] 13, 28, 34, 35, 46, 51, 85, 86, 87, 89, 162 |
| D08066 |
| [1] SRC |
D09664 |
Saracatinib |
[2] 6, 89 |
| [1] VEGFA |
D06409 |
Bevacizumab |
[9] 13, 34, 85, 86, 87, 89, 227, 280, 331 |
| 44 | FoxO signaling pathway 1 gene, 1 drug (DrugBank), 5 diseases shown |
[1] EGFR |
D03455 |
Cetuximab |
[5] 34, 51, 86, 89, 331 |
| 45 | GABAergic synapse 4 genes, 2 drugs (DrugBank), 15 diseases shown |
[3] ABAT, GAD1, GAD2 |
D00399 |
Valproic Acid |
[14] 2, 3, 5, 8, 26, 34, 65, 89, 90, 102, 222, 233, 256, 331 |
| [1] SRC |
D09664 |
Saracatinib |
[2] 6, 89 |
| 46 | Gap junction 4 genes, 4 drugs (DrugBank), 14 diseases shown |
[1] EGFR |
D03455 |
Cetuximab |
[5] 34, 51, 86, 89, 331 |
| [1] PDGFRA |
D01441 |
Imatinib |
[11] 13, 28, 34, 35, 46, 51, 85, 86, 87, 89, 162 |
| D08066 |
| [2] PDGFRA, PDGFRB |
D10481 |
Nintedanib |
[4] 51, 85, 89, 228 |
| [1] SRC |
D09664 |
Saracatinib |
[2] 6, 89 |
| 47 | Gastric acid secretion 1 gene, 1 drug (DrugBank), 8 diseases shown |
[1] SSTR2 |
D00442 |
Octreotide |
[8] 67, 75, 84, 85, 89, 96, 193, 227 |
| D06495 |
| 48 | Gastric cancer 3 genes, 5 drugs (DrugBank), 37 diseases shown |
[1] EGFR |
D03455 |
Cetuximab |
[5] 34, 51, 86, 89, 331 |
| [1] FGFR2 |
D10481 |
Nintedanib |
[4] 51, 85, 89, 228 |
| [1] MTOR |
D02714 |
Everolimus |
[9] 34, 67, 89, 96, 137, 157, 158, 228, 277 |
| D00753 |
Sirolimus |
[36] 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
| D06068 |
Temsirolimus |
[4] 13, 34, 89, 331 |
| 49 | Glioma 4 genes, 6 drugs (DrugBank), 40 diseases shown |
[1] EGFR |
D03455 |
Cetuximab |
[5] 34, 51, 86, 89, 331 |
| [1] MTOR |
D02714 |
Everolimus |
[9] 34, 67, 89, 96, 137, 157, 158, 228, 277 |
| D00753 |
Sirolimus |
[36] 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
| D06068 |
Temsirolimus |
[4] 13, 34, 89, 331 |
| [1] PDGFRA |
D01441 |
Imatinib |
[11] 13, 28, 34, 35, 46, 51, 85, 86, 87, 89, 162 |
| D08066 |
| [2] PDGFRA, PDGFRB |
D10481 |
Nintedanib |
[4] 51, 85, 89, 228 |
| 50 | GnRH secretion 3 genes, 1 drug (DrugBank), 14 diseases shown |
[3] CACNA1G, CACNA1H, CACNA1I |
D00399 |
Valproic Acid |
[14] 2, 3, 5, 8, 26, 34, 65, 89, 90, 102, 222, 233, 256, 331 |
| 51 | GnRH signaling pathway 2 genes, 2 drugs (DrugBank), 6 diseases shown |
[1] EGFR |
D03455 |
Cetuximab |
[5] 34, 51, 86, 89, 331 |
| [1] SRC |
D09664 |
Saracatinib |
[2] 6, 89 |
| 52 | Growth hormone synthesis, secretion and action 2 genes, 4 drugs (DrugBank), 41 diseases shown |
[1] MTOR |
D02714 |
Everolimus |
[9] 34, 67, 89, 96, 137, 157, 158, 228, 277 |
| D00753 |
Sirolimus |
[36] 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
| D06068 |
Temsirolimus |
[4] 13, 34, 89, 331 |
| [1] SSTR2 |
D00442 |
Octreotide |
[8] 67, 75, 84, 85, 89, 96, 193, 227 |
| D06495 |
| 53 | Hematopoietic cell lineage 1 gene, 1 drug (DrugBank), 11 diseases shown |
[1] KIT |
D01441 |
Imatinib |
[11] 13, 28, 34, 35, 46, 51, 85, 86, 87, 89, 162 |
| D08066 |
| 54 | Hepatitis B 1 gene, 1 drug (DrugBank), 2 diseases shown |
[1] SRC |
D09664 |
Saracatinib |
[2] 6, 89 |
| 55 | Hepatitis C 1 gene, 1 drug (DrugBank), 5 diseases shown |
[1] EGFR |
D03455 |
Cetuximab |
[5] 34, 51, 86, 89, 331 |
| 56 | Hepatocellular carcinoma 2 genes, 4 drugs (DrugBank), 37 diseases shown |
[1] EGFR |
D03455 |
Cetuximab |
[5] 34, 51, 86, 89, 331 |
| [1] MTOR |
D02714 |
Everolimus |
[9] 34, 67, 89, 96, 137, 157, 158, 228, 277 |
| D00753 |
Sirolimus |
[36] 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
| D06068 |
Temsirolimus |
[4] 13, 34, 89, 331 |
| 57 | Herpes simplex virus 1 infection 2 genes, 4 drugs (DrugBank), 38 diseases shown |
[1] MTOR |
D02714 |
Everolimus |
[9] 34, 67, 89, 96, 137, 157, 158, 228, 277 |
| D00753 |
Sirolimus |
[36] 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
| D06068 |
Temsirolimus |
[4] 13, 34, 89, 331 |
| [1] SRC |
D09664 |
Saracatinib |
[2] 6, 89 |
| 58 | HIF-1 signaling pathway 4 genes, 6 drugs (DrugBank), 39 diseases shown |
[1] EGFR |
D03455 |
Cetuximab |
[5] 34, 51, 86, 89, 331 |
| [1] FLT1 |
D10481 |
Nintedanib |
[4] 51, 85, 89, 228 |
| [1] MTOR |
D02714 |
Everolimus |
[9] 34, 67, 89, 96, 137, 157, 158, 228, 277 |
| D00753 |
Sirolimus |
[36] 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
| D06068 |
Temsirolimus |
[4] 13, 34, 89, 331 |
| [1] VEGFA |
D06409 |
Bevacizumab |
[9] 13, 34, 85, 86, 87, 89, 227, 280, 331 |
| 59 | Human cytomegalovirus infection 6 genes, 9 drugs (DrugBank), 46 diseases shown |
[1] EGFR |
D03455 |
Cetuximab |
[5] 34, 51, 86, 89, 331 |
| [1] MTOR |
D02714 |
Everolimus |
[9] 34, 67, 89, 96, 137, 157, 158, 228, 277 |
| D00753 |
Sirolimus |
[36] 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
| D06068 |
Temsirolimus |
[4] 13, 34, 89, 331 |
| [1] PDGFRA |
D01441 |
Imatinib |
[11] 13, 28, 34, 35, 46, 51, 85, 86, 87, 89, 162 |
| D08066 |
| D10481 |
Nintedanib |
[4] 51, 85, 89, 228 |
| [1] PTGS2 |
D00567 |
Celecoxib |
[9] 2, 3, 34, 46, 70, 89, 96, 161, 271 |
| [1] SRC |
D09664 |
Saracatinib |
[2] 6, 89 |
| [1] VEGFA |
D06409 |
Bevacizumab |
[9] 13, 34, 85, 86, 87, 89, 227, 280, 331 |
| 60 | Human immunodeficiency virus 1 infection 1 gene, 3 drugs (DrugBank), 37 diseases shown |
[1] MTOR |
D02714 |
Everolimus |
[9] 34, 67, 89, 96, 137, 157, 158, 228, 277 |
| D00753 |
Sirolimus |
[36] 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
| D06068 |
Temsirolimus |
[4] 13, 34, 89, 331 |
| 61 | Human papillomavirus infection 5 genes, 7 drugs (DrugBank), 43 diseases shown |
[1] EGFR |
D03455 |
Cetuximab |
[5] 34, 51, 86, 89, 331 |
| [1] MTOR |
D02714 |
Everolimus |
[9] 34, 67, 89, 96, 137, 157, 158, 228, 277 |
| D00753 |
Sirolimus |
[36] 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
| D06068 |
Temsirolimus |
[4] 13, 34, 89, 331 |
| [1] PDGFRB |
D10481 |
Nintedanib |
[4] 51, 85, 89, 228 |
| [1] PTGS2 |
D00567 |
Celecoxib |
[9] 2, 3, 34, 46, 70, 89, 96, 161, 271 |
| [1] VEGFA |
D06409 |
Bevacizumab |
[9] 13, 34, 85, 86, 87, 89, 227, 280, 331 |
| 62 | IL-17 signaling pathway 1 gene, 1 drug (DrugBank), 9 diseases shown |
[1] PTGS2 |
D00567 |
Celecoxib |
[9] 2, 3, 34, 46, 70, 89, 96, 161, 271 |
| 63 | Inflammatory mediator regulation of TRP channels 1 gene, 1 drug (DrugBank), 2 diseases shown |
[1] SRC |
D09664 |
Saracatinib |
[2] 6, 89 |
| 64 | Insulin resistance 1 gene, 3 drugs (DrugBank), 37 diseases shown |
[1] MTOR |
D02714 |
Everolimus |
[9] 34, 67, 89, 96, 137, 157, 158, 228, 277 |
| D00753 |
Sirolimus |
[36] 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
| D06068 |
Temsirolimus |
[4] 13, 34, 89, 331 |
| 65 | Insulin signaling pathway 1 gene, 3 drugs (DrugBank), 37 diseases shown |
[1] MTOR |
D02714 |
Everolimus |
[9] 34, 67, 89, 96, 137, 157, 158, 228, 277 |
| D00753 |
Sirolimus |
[36] 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
| D06068 |
Temsirolimus |
[4] 13, 34, 89, 331 |
| 66 | JAK-STAT signaling pathway 4 genes, 6 drugs (DrugBank), 40 diseases shown |
[1] EGFR |
D03455 |
Cetuximab |
[5] 34, 51, 86, 89, 331 |
| [1] MTOR |
D02714 |
Everolimus |
[9] 34, 67, 89, 96, 137, 157, 158, 228, 277 |
| D00753 |
Sirolimus |
[36] 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
| D06068 |
Temsirolimus |
[4] 13, 34, 89, 331 |
| [1] PDGFRA |
D01441 |
Imatinib |
[11] 13, 28, 34, 35, 46, 51, 85, 86, 87, 89, 162 |
| D08066 |
| [2] PDGFRA, PDGFRB |
D10481 |
Nintedanib |
[4] 51, 85, 89, 228 |
| 67 | Kaposi sarcoma-associated herpesvirus infection 4 genes, 6 drugs (DrugBank), 44 diseases shown |
[1] MTOR |
D02714 |
Everolimus |
[9] 34, 67, 89, 96, 137, 157, 158, 228, 277 |
| D00753 |
Sirolimus |
[36] 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
| D06068 |
Temsirolimus |
[4] 13, 34, 89, 331 |
| [1] PTGS2 |
D00567 |
Celecoxib |
[9] 2, 3, 34, 46, 70, 89, 96, 161, 271 |
| [1] SRC |
D09664 |
Saracatinib |
[2] 6, 89 |
| [1] VEGFA |
D06409 |
Bevacizumab |
[9] 13, 34, 85, 86, 87, 89, 227, 280, 331 |
| 68 | Leishmaniasis 1 gene, 1 drug (DrugBank), 9 diseases shown |
[1] PTGS2 |
D00567 |
Celecoxib |
[9] 2, 3, 34, 46, 70, 89, 96, 161, 271 |
| 69 | Longevity regulating pathway 1 gene, 3 drugs (DrugBank), 37 diseases shown |
[1] MTOR |
D02714 |
Everolimus |
[9] 34, 67, 89, 96, 137, 157, 158, 228, 277 |
| D00753 |
Sirolimus |
[36] 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
| D06068 |
Temsirolimus |
[4] 13, 34, 89, 331 |
| 70 | Longevity regulating pathway - multiple species 1 gene, 3 drugs (DrugBank), 37 diseases shown |
[1] MTOR |
D02714 |
Everolimus |
[9] 34, 67, 89, 96, 137, 157, 158, 228, 277 |
| D00753 |
Sirolimus |
[36] 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
| D06068 |
Temsirolimus |
[4] 13, 34, 89, 331 |
| 71 | MAPK signaling pathway 14 genes, 5 drugs (DrugBank), 26 diseases shown |
[3] CACNA1G, CACNA1H, CACNA1I |
D00399 |
Valproic Acid |
[14] 2, 3, 5, 8, 26, 34, 65, 89, 90, 102, 222, 233, 256, 331 |
| [1] EGFR |
D03455 |
Cetuximab |
[5] 34, 51, 86, 89, 331 |
| [8] FGFR1, FGFR2, FGFR3, FLT1, FLT4, KDR, PDGFRA, PDGFRB |
D10481 |
Nintedanib |
[4] 51, 85, 89, 228 |
| [2] KIT, PDGFRA |
D01441 |
Imatinib |
[11] 13, 28, 34, 35, 46, 51, 85, 86, 87, 89, 162 |
| D08066 |
| [1] VEGFA |
D06409 |
Bevacizumab |
[9] 13, 34, 85, 86, 87, 89, 227, 280, 331 |
| 72 | Melanogenesis 1 gene, 1 drug (DrugBank), 11 diseases shown |
[1] KIT |
D01441 |
Imatinib |
[11] 13, 28, 34, 35, 46, 51, 85, 86, 87, 89, 162 |
| D08066 |
| 73 | Melanoma 4 genes, 3 drugs (DrugBank), 13 diseases shown |
[1] EGFR |
D03455 |
Cetuximab |
[5] 34, 51, 86, 89, 331 |
| [3] FGFR1, PDGFRA, PDGFRB |
D10481 |
Nintedanib |
[4] 51, 85, 89, 228 |
| [1] PDGFRA |
D01441 |
Imatinib |
[11] 13, 28, 34, 35, 46, 51, 85, 86, 87, 89, 162 |
| D08066 |
| 74 | Metabolic pathways 7 genes, 4 drugs (DrugBank), 36 diseases shown |
[4] ABAT, ALDH5A1, GAD1, GAD2 |
D00399 |
Valproic Acid |
[14] 2, 3, 5, 8, 26, 34, 65, 89, 90, 102, 222, 233, 256, 331 |
| [1] CYP19A1 |
D00964 |
Letrozole |
[2] 81, 89 |
| [1] HMGCR |
D00434 |
Simvastatin |
[19] 6, 13, 15, 34, 46, 49, 51, 66, 79, 86, 89, 94, 158, 162, 195, 265, 298, 299, 310 |
| [1] PTGS2 |
D00567 |
Celecoxib |
[9] 2, 3, 34, 46, 70, 89, 96, 161, 271 |
| 75 | MicroRNAs in cancer 8 genes, 9 drugs (DrugBank), 46 diseases shown |
[1] ABL1 |
D09664 |
Saracatinib |
[2] 6, 89 |
| [2] ABL1, PDGFRA |
D01441 |
Imatinib |
[11] 13, 28, 34, 35, 46, 51, 85, 86, 87, 89, 162 |
| D08066 |
| [1] EGFR |
D03455 |
Cetuximab |
[5] 34, 51, 86, 89, 331 |
| [3] FGFR3, PDGFRA, PDGFRB |
D10481 |
Nintedanib |
[4] 51, 85, 89, 228 |
| [1] MTOR |
D02714 |
Everolimus |
[9] 34, 67, 89, 96, 137, 157, 158, 228, 277 |
| D00753 |
Sirolimus |
[36] 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
| D06068 |
Temsirolimus |
[4] 13, 34, 89, 331 |
| [1] PTGS2 |
D00567 |
Celecoxib |
[9] 2, 3, 34, 46, 70, 89, 96, 161, 271 |
| [1] VEGFA |
D06409 |
Bevacizumab |
[9] 13, 34, 85, 86, 87, 89, 227, 280, 331 |
| 76 | Mitophagy - animal 1 gene, 1 drug (DrugBank), 2 diseases shown |
[1] SRC |
D09664 |
Saracatinib |
[2] 6, 89 |
| 77 | mTOR signaling pathway 1 gene, 3 drugs (DrugBank), 37 diseases shown |
[1] MTOR |
D02714 |
Everolimus |
[9] 34, 67, 89, 96, 137, 157, 158, 228, 277 |
| D00753 |
Sirolimus |
[36] 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
| D06068 |
Temsirolimus |
[4] 13, 34, 89, 331 |
| 78 | Neuroactive ligand-receptor interaction 2 genes, 2 drugs (DrugBank), 19 diseases shown |
[1] ADRB2 |
D02147 |
Salbutamol |
[13] 3, 11, 12, 13, 49, 85, 86, 89, 113, 228, 231, 256, 299 |
| [1] SSTR2 |
D00442 |
Octreotide |
[8] 67, 75, 84, 85, 89, 96, 193, 227 |
| D06495 |
| 79 | Neurotrophin signaling pathway 1 gene, 2 drugs (DrugBank), 12 diseases shown |
[1] ABL1 |
D01441 |
Imatinib |
[11] 13, 28, 34, 35, 46, 51, 85, 86, 87, 89, 162 |
| D08066 |
| D09664 |
Saracatinib |
[2] 6, 89 |
| 80 | NF-kappa B signaling pathway 1 gene, 1 drug (DrugBank), 9 diseases shown |
[1] PTGS2 |
D00567 |
Celecoxib |
[9] 2, 3, 34, 46, 70, 89, 96, 161, 271 |
| 81 | Non-small cell lung cancer 1 gene, 1 drug (DrugBank), 5 diseases shown |
[1] EGFR |
D03455 |
Cetuximab |
[5] 34, 51, 86, 89, 331 |
| 82 | Ovarian steroidogenesis 2 genes, 2 drugs (DrugBank), 10 diseases shown |
[1] CYP19A1 |
D00964 |
Letrozole |
[2] 81, 89 |
| [1] PTGS2 |
D00567 |
Celecoxib |
[9] 2, 3, 34, 46, 70, 89, 96, 161, 271 |
| 83 | Oxytocin signaling pathway 3 genes, 3 drugs (DrugBank), 13 diseases shown |
[1] EGFR |
D03455 |
Cetuximab |
[5] 34, 51, 86, 89, 331 |
| [1] PTGS2 |
D00567 |
Celecoxib |
[9] 2, 3, 34, 46, 70, 89, 96, 161, 271 |
| [1] SRC |
D09664 |
Saracatinib |
[2] 6, 89 |
| 84 | Pancreatic cancer 3 genes, 5 drugs (DrugBank), 39 diseases shown |
[1] EGFR |
D03455 |
Cetuximab |
[5] 34, 51, 86, 89, 331 |
| [1] MTOR |
D02714 |
Everolimus |
[9] 34, 67, 89, 96, 137, 157, 158, 228, 277 |
| D00753 |
Sirolimus |
[36] 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
| D06068 |
Temsirolimus |
[4] 13, 34, 89, 331 |
| [1] VEGFA |
D06409 |
Bevacizumab |
[9] 13, 34, 85, 86, 87, 89, 227, 280, 331 |
| 85 | Parathyroid hormone synthesis, secretion and action 2 genes, 2 drugs (DrugBank), 7 diseases shown |
[1] EGFR |
D03455 |
Cetuximab |
[5] 34, 51, 86, 89, 331 |
| [1] FGFR1 |
D10481 |
Nintedanib |
[4] 51, 85, 89, 228 |
| 86 | Pathogenic Escherichia coli infection 1 gene, 2 drugs (DrugBank), 12 diseases shown |
[1] ABL1 |
D01441 |
Imatinib |
[11] 13, 28, 34, 35, 46, 51, 85, 86, 87, 89, 162 |
| D08066 |
| D09664 |
Saracatinib |
[2] 6, 89 |
| 87 | Pathways in cancer 12 genes, 9 drugs (DrugBank), 46 diseases shown |
[1] ABL1 |
D09664 |
Saracatinib |
[2] 6, 89 |
| [3] ABL1, KIT, PDGFRA |
D01441 |
Imatinib |
[11] 13, 28, 34, 35, 46, 51, 85, 86, 87, 89, 162 |
| D08066 |
| [1] EGFR |
D03455 |
Cetuximab |
[5] 34, 51, 86, 89, 331 |
| [6] FGFR1, FGFR2, FGFR3, FLT4, PDGFRA, PDGFRB |
D10481 |
Nintedanib |
[4] 51, 85, 89, 228 |
| [1] MTOR |
D02714 |
Everolimus |
[9] 34, 67, 89, 96, 137, 157, 158, 228, 277 |
| D00753 |
Sirolimus |
[36] 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
| D06068 |
Temsirolimus |
[4] 13, 34, 89, 331 |
| [1] PTGS2 |
D00567 |
Celecoxib |
[9] 2, 3, 34, 46, 70, 89, 96, 161, 271 |
| [1] VEGFA |
D06409 |
Bevacizumab |
[9] 13, 34, 85, 86, 87, 89, 227, 280, 331 |
| 88 | PD-L1 expression and PD-1 checkpoint pathway in cancer 2 genes, 4 drugs (DrugBank), 37 diseases shown |
[1] EGFR |
D03455 |
Cetuximab |
[5] 34, 51, 86, 89, 331 |
| [1] MTOR |
D02714 |
Everolimus |
[9] 34, 67, 89, 96, 137, 157, 158, 228, 277 |
| D00753 |
Sirolimus |
[36] 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
| D06068 |
Temsirolimus |
[4] 13, 34, 89, 331 |
| 89 | Phospholipase D signaling pathway 5 genes, 6 drugs (DrugBank), 40 diseases shown |
[1] EGFR |
D03455 |
Cetuximab |
[5] 34, 51, 86, 89, 331 |
| [2] KIT, PDGFRA |
D01441 |
Imatinib |
[11] 13, 28, 34, 35, 46, 51, 85, 86, 87, 89, 162 |
| D08066 |
| [1] MTOR |
D02714 |
Everolimus |
[9] 34, 67, 89, 96, 137, 157, 158, 228, 277 |
| D00753 |
Sirolimus |
[36] 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
| D06068 |
Temsirolimus |
[4] 13, 34, 89, 331 |
| [2] PDGFRA, PDGFRB |
D10481 |
Nintedanib |
[4] 51, 85, 89, 228 |
| 90 | PI3K-Akt signaling pathway 12 genes, 7 drugs (DrugBank), 41 diseases shown |
[1] EGFR |
D03455 |
Cetuximab |
[5] 34, 51, 86, 89, 331 |
| [8] FGFR1, FGFR2, FGFR3, FLT1, FLT4, KDR, PDGFRA, PDGFRB |
D10481 |
Nintedanib |
[4] 51, 85, 89, 228 |
| [2] KIT, PDGFRA |
D01441 |
Imatinib |
[11] 13, 28, 34, 35, 46, 51, 85, 86, 87, 89, 162 |
| D08066 |
| [1] MTOR |
D02714 |
Everolimus |
[9] 34, 67, 89, 96, 137, 157, 158, 228, 277 |
| D00753 |
Sirolimus |
[36] 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
| D06068 |
Temsirolimus |
[4] 13, 34, 89, 331 |
| [1] VEGFA |
D06409 |
Bevacizumab |
[9] 13, 34, 85, 86, 87, 89, 227, 280, 331 |
| 91 | Platelet activation 1 gene, 1 drug (DrugBank), 2 diseases shown |
[1] SRC |
D09664 |
Saracatinib |
[2] 6, 89 |
| 92 | Prolactin signaling pathway 1 gene, 1 drug (DrugBank), 2 diseases shown |
[1] SRC |
D09664 |
Saracatinib |
[2] 6, 89 |
| 93 | Propanoate metabolism 1 gene, 1 drug (DrugBank), 14 diseases shown |
[1] ABAT |
D00399 |
Valproic Acid |
[14] 2, 3, 5, 8, 26, 34, 65, 89, 90, 102, 222, 233, 256, 331 |
| 94 | Prostate cancer 6 genes, 6 drugs (DrugBank), 40 diseases shown |
[1] EGFR |
D03455 |
Cetuximab |
[5] 34, 51, 86, 89, 331 |
| [4] FGFR1, FGFR2, PDGFRA, PDGFRB |
D10481 |
Nintedanib |
[4] 51, 85, 89, 228 |
| [1] MTOR |
D02714 |
Everolimus |
[9] 34, 67, 89, 96, 137, 157, 158, 228, 277 |
| D00753 |
Sirolimus |
[36] 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
| D06068 |
Temsirolimus |
[4] 13, 34, 89, 331 |
| [1] PDGFRA |
D01441 |
Imatinib |
[11] 13, 28, 34, 35, 46, 51, 85, 86, 87, 89, 162 |
| D08066 |
| 95 | Proteoglycans in cancer 6 genes, 7 drugs (DrugBank), 40 diseases shown |
[1] EGFR |
D03455 |
Cetuximab |
[5] 34, 51, 86, 89, 331 |
| [2] FGFR1, KDR |
D10481 |
Nintedanib |
[4] 51, 85, 89, 228 |
| [1] MTOR |
D02714 |
Everolimus |
[9] 34, 67, 89, 96, 137, 157, 158, 228, 277 |
| D00753 |
Sirolimus |
[36] 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
| D06068 |
Temsirolimus |
[4] 13, 34, 89, 331 |
| [1] SRC |
D09664 |
Saracatinib |
[2] 6, 89 |
| [1] VEGFA |
D06409 |
Bevacizumab |
[9] 13, 34, 85, 86, 87, 89, 227, 280, 331 |
| 96 | Rap1 signaling pathway 12 genes, 5 drugs (DrugBank), 16 diseases shown |
[1] EGFR |
D03455 |
Cetuximab |
[5] 34, 51, 86, 89, 331 |
| [8] FGFR1, FGFR2, FGFR3, FLT1, FLT4, KDR, PDGFRA, PDGFRB |
D10481 |
Nintedanib |
[4] 51, 85, 89, 228 |
| [2] KIT, PDGFRA |
D01441 |
Imatinib |
[11] 13, 28, 34, 35, 46, 51, 85, 86, 87, 89, 162 |
| D08066 |
| [1] SRC |
D09664 |
Saracatinib |
[2] 6, 89 |
| [1] VEGFA |
D06409 |
Bevacizumab |
[9] 13, 34, 85, 86, 87, 89, 227, 280, 331 |
| 97 | Ras signaling pathway 12 genes, 5 drugs (DrugBank), 16 diseases shown |
[1] ABL1 |
D09664 |
Saracatinib |
[2] 6, 89 |
| [3] ABL1, KIT, PDGFRA |
D01441 |
Imatinib |
[11] 13, 28, 34, 35, 46, 51, 85, 86, 87, 89, 162 |
| D08066 |
| [1] EGFR |
D03455 |
Cetuximab |
[5] 34, 51, 86, 89, 331 |
| [8] FGFR1, FGFR2, FGFR3, FLT1, FLT4, KDR, PDGFRA, PDGFRB |
D10481 |
Nintedanib |
[4] 51, 85, 89, 228 |
| [1] VEGFA |
D06409 |
Bevacizumab |
[9] 13, 34, 85, 86, 87, 89, 227, 280, 331 |
| 98 | Regulation of actin cytoskeleton 7 genes, 4 drugs (DrugBank), 14 diseases shown |
[1] EGFR |
D03455 |
Cetuximab |
[5] 34, 51, 86, 89, 331 |
| [5] FGFR1, FGFR2, FGFR3, PDGFRA, PDGFRB |
D10481 |
Nintedanib |
[4] 51, 85, 89, 228 |
| [1] PDGFRA |
D01441 |
Imatinib |
[11] 13, 28, 34, 35, 46, 51, 85, 86, 87, 89, 162 |
| D08066 |
| [1] SRC |
D09664 |
Saracatinib |
[2] 6, 89 |
| 99 | Regulation of lipolysis in adipocytes 2 genes, 2 drugs (DrugBank), 20 diseases shown |
[1] ADRB2 |
D02147 |
Salbutamol |
[13] 3, 11, 12, 13, 49, 85, 86, 89, 113, 228, 231, 256, 299 |
| [1] PTGS2 |
D00567 |
Celecoxib |
[9] 2, 3, 34, 46, 70, 89, 96, 161, 271 |
| 100 | Relaxin signaling pathway 3 genes, 3 drugs (DrugBank), 11 diseases shown |
[1] EGFR |
D03455 |
Cetuximab |
[5] 34, 51, 86, 89, 331 |
| [1] SRC |
D09664 |
Saracatinib |
[2] 6, 89 |
| [1] VEGFA |
D06409 |
Bevacizumab |
[9] 13, 34, 85, 86, 87, 89, 227, 280, 331 |
| 101 | Renal cell carcinoma 1 gene, 1 drug (DrugBank), 9 diseases shown |
[1] VEGFA |
D06409 |
Bevacizumab |
[9] 13, 34, 85, 86, 87, 89, 227, 280, 331 |
| 102 | Renin secretion 1 gene, 1 drug (DrugBank), 13 diseases shown |
[1] ADRB2 |
D02147 |
Salbutamol |
[13] 3, 11, 12, 13, 49, 85, 86, 89, 113, 228, 231, 256, 299 |
| 103 | Retrograde endocannabinoid signaling 1 gene, 1 drug (DrugBank), 9 diseases shown |
[1] PTGS2 |
D00567 |
Celecoxib |
[9] 2, 3, 34, 46, 70, 89, 96, 161, 271 |
| 104 | Rheumatoid arthritis 2 genes, 2 drugs (DrugBank), 11 diseases shown |
[1] FLT1 |
D10481 |
Nintedanib |
[4] 51, 85, 89, 228 |
| [1] VEGFA |
D06409 |
Bevacizumab |
[9] 13, 34, 85, 86, 87, 89, 227, 280, 331 |
| 105 | Salivary secretion 1 gene, 1 drug (DrugBank), 13 diseases shown |
[1] ADRB2 |
D02147 |
Salbutamol |
[13] 3, 11, 12, 13, 49, 85, 86, 89, 113, 228, 231, 256, 299 |
| 106 | Serotonergic synapse 1 gene, 1 drug (DrugBank), 9 diseases shown |
[1] PTGS2 |
D00567 |
Celecoxib |
[9] 2, 3, 34, 46, 70, 89, 96, 161, 271 |
| 107 | Shigellosis 4 genes, 6 drugs (DrugBank), 41 diseases shown |
[1] ABL1 |
D01441 |
Imatinib |
[11] 13, 28, 34, 35, 46, 51, 85, 86, 87, 89, 162 |
| D08066 |
| [2] ABL1, SRC |
D09664 |
Saracatinib |
[2] 6, 89 |
| [1] EGFR |
D03455 |
Cetuximab |
[5] 34, 51, 86, 89, 331 |
| [1] MTOR |
D02714 |
Everolimus |
[9] 34, 67, 89, 96, 137, 157, 158, 228, 277 |
| D00753 |
Sirolimus |
[36] 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
| D06068 |
Temsirolimus |
[4] 13, 34, 89, 331 |
| 108 | Signaling pathways regulating pluripotency of stem cells 3 genes, 1 drug (DrugBank), 4 diseases shown |
[3] FGFR1, FGFR2, FGFR3 |
D10481 |
Nintedanib |
[4] 51, 85, 89, 228 |
| 109 | Small cell lung cancer 1 gene, 1 drug (DrugBank), 9 diseases shown |
[1] PTGS2 |
D00567 |
Celecoxib |
[9] 2, 3, 34, 46, 70, 89, 96, 161, 271 |
| 110 | Steroid hormone biosynthesis 1 gene, 1 drug (DrugBank), 2 diseases shown |
[1] CYP19A1 |
D00964 |
Letrozole |
[2] 81, 89 |
| 111 | Taurine and hypotaurine metabolism 2 genes, 1 drug (DrugBank), 14 diseases shown |
[2] GAD1, GAD2 |
D00399 |
Valproic Acid |
[14] 2, 3, 5, 8, 26, 34, 65, 89, 90, 102, 222, 233, 256, 331 |
| 112 | Terpenoid backbone biosynthesis 1 gene, 1 drug (DrugBank), 19 diseases shown |
[1] HMGCR |
D00434 |
Simvastatin |
[19] 6, 13, 15, 34, 46, 49, 51, 66, 79, 86, 89, 94, 158, 162, 195, 265, 298, 299, 310 |
| 113 | Th17 cell differentiation 1 gene, 3 drugs (DrugBank), 37 diseases shown |
[1] MTOR |
D02714 |
Everolimus |
[9] 34, 67, 89, 96, 137, 157, 158, 228, 277 |
| D00753 |
Sirolimus |
[36] 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
| D06068 |
Temsirolimus |
[4] 13, 34, 89, 331 |
| 114 | Thermogenesis 2 genes, 4 drugs (DrugBank), 37 diseases shown |
[1] FGFR1 |
D10481 |
Nintedanib |
[4] 51, 85, 89, 228 |
| [1] MTOR |
D02714 |
Everolimus |
[9] 34, 67, 89, 96, 137, 157, 158, 228, 277 |
| D00753 |
Sirolimus |
[36] 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
| D06068 |
Temsirolimus |
[4] 13, 34, 89, 331 |
| 115 | Thyroid hormone signaling pathway 2 genes, 4 drugs (DrugBank), 38 diseases shown |
[1] MTOR |
D02714 |
Everolimus |
[9] 34, 67, 89, 96, 137, 157, 158, 228, 277 |
| D00753 |
Sirolimus |
[36] 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
| D06068 |
Temsirolimus |
[4] 13, 34, 89, 331 |
| [1] SRC |
D09664 |
Saracatinib |
[2] 6, 89 |
| 116 | Tight junction 1 gene, 1 drug (DrugBank), 2 diseases shown |
[1] SRC |
D09664 |
Saracatinib |
[2] 6, 89 |
| 117 | TNF signaling pathway 1 gene, 1 drug (DrugBank), 9 diseases shown |
[1] PTGS2 |
D00567 |
Celecoxib |
[9] 2, 3, 34, 46, 70, 89, 96, 161, 271 |
| 118 | Transcriptional misregulation in cancer 1 gene, 1 drug (DrugBank), 4 diseases shown |
[1] FLT1 |
D10481 |
Nintedanib |
[4] 51, 85, 89, 228 |
| 119 | Tuberculosis 1 gene, 1 drug (DrugBank), 2 diseases shown |
[1] SRC |
D09664 |
Saracatinib |
[2] 6, 89 |
| 120 | Type I diabetes mellitus 2 genes, 1 drug (DrugBank), 14 diseases shown |
[2] GAD1, GAD2 |
D00399 |
Valproic Acid |
[14] 2, 3, 5, 8, 26, 34, 65, 89, 90, 102, 222, 233, 256, 331 |
| 121 | Type II diabetes mellitus 2 genes, 4 drugs (DrugBank), 44 diseases shown |
[1] CACNA1G |
D00399 |
Valproic Acid |
[14] 2, 3, 5, 8, 26, 34, 65, 89, 90, 102, 222, 233, 256, 331 |
| [1] MTOR |
D02714 |
Everolimus |
[9] 34, 67, 89, 96, 137, 157, 158, 228, 277 |
| D00753 |
Sirolimus |
[36] 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
| D06068 |
Temsirolimus |
[4] 13, 34, 89, 331 |
| 122 | Valine, leucine and isoleucine degradation 1 gene, 1 drug (DrugBank), 14 diseases shown |
[1] ABAT |
D00399 |
Valproic Acid |
[14] 2, 3, 5, 8, 26, 34, 65, 89, 90, 102, 222, 233, 256, 331 |
| 123 | VEGF signaling pathway 4 genes, 4 drugs (DrugBank), 19 diseases shown |
[1] KDR |
D10481 |
Nintedanib |
[4] 51, 85, 89, 228 |
| [1] PTGS2 |
D00567 |
Celecoxib |
[9] 2, 3, 34, 46, 70, 89, 96, 161, 271 |
| [1] SRC |
D09664 |
Saracatinib |
[2] 6, 89 |
| [1] VEGFA |
D06409 |
Bevacizumab |
[9] 13, 34, 85, 86, 87, 89, 227, 280, 331 |
| 124 | Viral carcinogenesis 1 gene, 1 drug (DrugBank), 2 diseases shown |
[1] SRC |
D09664 |
Saracatinib |
[2] 6, 89 |
| 125 | Viral myocarditis 1 gene, 2 drugs (DrugBank), 12 diseases shown |
[1] ABL1 |
D01441 |
Imatinib |
[11] 13, 28, 34, 35, 46, 51, 85, 86, 87, 89, 162 |
| D08066 |
| D09664 |
Saracatinib |
[2] 6, 89 |
| 126 | Yersinia infection 1 gene, 1 drug (DrugBank), 2 diseases shown |
[1] SRC |
D09664 |
Saracatinib |
[2] 6, 89 |